Automate Your Wheel Strategy on ALVO
With Tiblio's Option Bot, you can configure your own wheel strategy including ALVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ALVO
- Rev/Share 1.9023
- Book/Share -0.5887
- PB -8.8496
- Debt/Equity -7.2536
- CurrentRatio 1.4207
- ROIC 0.0374
- MktCap 1623442012.0
- FreeCF/Share -0.3779
- PFCF -14.3095
- PE 22.4971
- Debt/Assets 0.9099
- DivYield 0
- ROE -0.2611
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 2
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | ALVO | Barclays | -- | Underweight | -- | $5 | Dec. 9, 2025 |
| Downgrade | ALVO | Deutsche Bank | Buy | Hold | -- | $8 | Nov. 4, 2025 |
| Upgrade | ALVO | Morgan Stanley | Equal Weight | Overweight | -- | $14 | Oct. 14, 2025 |
| Upgrade | ALVO | Deutsche Bank | Hold | Buy | -- | $14 | Sept. 23, 2025 |
| Initiation | ALVO | UBS | -- | Buy | -- | $18 | Feb. 14, 2025 |
News
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
ROSEN, A LONGSTANDING LAW FIRM, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Published: January 28, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: January 16, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
ALVO INVESTOR ALERT: Hagens Berman Investigates Alvotech (ALVO) for Potential Securities Fraud Following Massive FDA-Induced Stock Crash
Published: January 14, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 14, 2026 /PRNewswire/ -- National shareholder rights firm Hagens Berman is investigating Alvotech (NASDAQ: ALVO) regarding the propriety of its disclosures concerning the company's manufacturing operations and the regulatory status of its lead biosimilar candidate, AVT05. The investigation follows a staggering 34% stock drop after Alvotech revealed it received a "Complete Response Letter" (CRL) from the FDA.
Read More
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
Published: January 13, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Beyond Meat, Inc. (NASDAQ:BYND) and Alvotech (NASDAQ:ALVO). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
Transactions of Managers and Closely Associated Persons
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of shares in Alvotech by ATP Holdings ehf. The shares were aquired in two transactions, 4,812,257 shares on December 17, 2025 and 2,110,640 shares on December 19, 2025. The transaction price was SEK 44.06 per share.
Read More
Transactions of Managers and Closely Associated Persons
Published: January 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
Attached is a copy of a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the acquisition of 7,007,321 shares in Alvotech by Alvogen Lux Holdings S.a. r.l. at a price of SEK 44.06 per share. The date of the transaction was December 17, 2025.
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: January 01, 2026 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Jan. 01, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
Changes in company's own shares
Published: December 29, 2025 by: GlobeNewsWire
Sentiment: Neutral
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding changes in company's own shares. Attachment Alvotech Own Shares Notification 29 Dec 2025
Read More
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Published: December 25, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 25, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: December 23, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 23, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
Alvotech's Financial Calendar for 2026
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after the close of U.S. markets. An investor call is held on the following day, after release of the results.
Read More
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that launches are underway in Europe for Gobivaz® (golimumab), Alvotech's biosimilar to Simponi® (golimumab), also known as AVT05 (prefilled syringe and autoinjector). Gobivaz is the first marketed biosimilar to Simponi worldwide. It is being commercialized exclusively in Europe by Alvotech's partner, Advanz Pharma Holdco Limited (“Advanz Pharma”).
Read More
Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma
Published: December 22, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that launches are underway in Europe for Gobivaz® (golimumab), Alvotech's biosimilar to Simponi® (golimumab), also known as AVT05 (prefilled syringe and autoinjector). Gobivaz is the first marketed biosimilar to Simponi worldwide. It is being commercialized exclusively in Europe by Alvotech's partner, Advanz Pharma Holdco Limited (“Advanz Pharma”).
Read More
Alvotech Investor News: Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO
Published: December 19, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 19, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Published: December 16, 2025 by: Seeking Alpha
Sentiment: Neutral
Alvotech (ALVO) Discusses Launch of $125 Million Commercial Bond Offering and Business Update Transcript
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: December 16, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
Published: December 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
Published: December 11, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alvotech ("Alvotech" or the "Company") (NASDAQ: ALVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: December 11, 2025 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO , Dec. 11, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.
Read More
Rosen Law Firm Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO
Published: December 04, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. So What: If you purchased Alvotech securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rose.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech - ALVO
Published: November 20, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alvotech ("Alvotech" or the "Company") (NASDAQ: ALVO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 19, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 14, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
Alvotech (ALVO) Q3 2025 Earnings Call Transcript
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Neutral
Alvotech ( ALVO ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Benedikt Stefansson - VP of Investor Relations and Global Communications Robert Wessman - CEO, Founder & Executive Chairman Joseph McClellan - Chief Scientific & Technical Officer Linda Jonsdottir - Chief Financial Officer Conference Call Participants Ashwani Verma - UBS Investment Bank, Research Division Thibault Boutherin - Morgan Stanley, Research Division Arvid Necander - DNB Carnegie, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Alvotech Q3 2025 Earnings Conference Call.
Read More
ALVO ALERT: Levi & Korsinsky Investigates Alvotech for Possible Securities Fraud Violations
Published: November 13, 2025 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - November 13, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Alvotech ("Alvotech") (NASDAQ: ALVO) concerning possible violations of federal securities laws. On November 2, 2025, Alvotech published a press release notifying investors that the Company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its Biologics License Application (BLA) for ATV05.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 13, 2025 by: PRNewsWire
Sentiment: Neutral
ALVO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO , Nov. 13, 2025 /PRNewswire/ -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts. The firm urges investors in Alvotech who suffered significant losses to submit your losses now.
Read More
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Published: November 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Shareholder rights firm Hagens Berman is scrutinizing Icelandic biopharmaceutical company Alvotech (NASDAQ: ALVO) over the propriety of its disclosures regarding its lead drug candidate and its manufacturing operations, following a dramatic revision to the company's full-year financial forecasts.
Read More
About Alvotech (ALVO)
- IPO Date 2022-06-16
- Website https://www.alvotech.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Vilhelm Robert Wessman
- Employees 1012